GenSight will participate to EURETINA 2019 Congress, 5-8 September, Paris, France.

A Free Paper abstract has been accepted for oral presentation on GS030, our lead gene therapy product candidate, an innovative optogenetic treatment that started a Phase I/II PIONEER clinical trial in Europe and US with patients affected by Retinitis Pigmentosa (RP).

GS030 – Optogenetics in Retinitis Pigmentosa (RP)

Free paper for oral presentation

Title –  A Phase 1/2 optogenetic retinal gene therapy clinical trial for non-syndromic retinitis pigmentosa (PIONEER study)

  • Abstract Author: Miss Simona Degli Esposti, Locum Research Consultant, NIHR Clinical Research Facility, Moorfields Eye Hospital NHS Foundation Trust (UK)